{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:02:35Z","timestamp":1772802155372,"version":"3.50.1"},"reference-count":36,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sinovac Biotech Co., Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: Sabin-strain inactivated poliovirus vaccine has been increasingly incorporated into routine immunization programs as part of the global strategy to eradicate poliomyelitis. As childhood immunization schedules become more complex, concerns persist regarding the safety of concomitant vaccination. Although randomized controlled trials and regional surveillance studies have demonstrated acceptable safety profiles, additional population-based real-world evidence remains valuable for evaluating the safety of sIPV administered concomitantly with other vaccines under routine programmatic conditions. Methods: A retrospective observational study was conducted using vaccination records and adverse events following immunization surveillance data collected in Liaoning Province, China, between 1 January 2022 and 30 June 2025. All reported adverse events following immunization following Sabin-strain inactivated poliovirus vaccine administration were extracted from the Chinese National AEFI Surveillance System. The reporting rates were calculated per 100,000 administered doses. Multivariable Poisson regression models with robust variance estimation were used to estimate adjusted rate ratios and 95% confidence intervals comparing standalone and concomitant sIPV administration, adjusting for sex, age in months, dose number, and city. Interaction analyses between vaccination mode and dose number were additionally performed. Results: A total of 205,576 sIPV doses were administered, including 144,724 doses administered alone and 60,852 doses administered concomitantly with other vaccines. Fifty-six adverse events following immunization were reported, corresponding to an overall reporting rate of 27.24 per 100,000 doses. Most reported adverse events following immunization were general reactions (91.07%), and all occurred within seven days after vaccination. The reporting rates for sIPV administered alone and concomitantly were 26.26 and 29.58 per 100,000 doses, respectively, with no significant difference between groups (p = 0.7869). After adjustment, concomitant sIPV administration was not associated with an increased risk of adverse events following immunization compared with standalone administration (adjusted rate ratios = 1.13, 95% confidence intervals: 0.59\u20132.16). No significant interaction between vaccination mode and dose number was identified. Conclusions: Sabin-strain inactivated poliovirus vaccine demonstrated a favorable safety profile when administered either alone or concomitantly with other vaccines. These findings support the continued use of flexible and synchronized vaccination strategies involving Sabin-strain inactivated poliovirus vaccine in routine immunization programs.<\/jats:p>","DOI":"10.3390\/vaccines14030241","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:22:14Z","timestamp":1772788934000},"page":"241","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety of Sabin-Strain Inactivated Poliovirus Vaccine Administered Alone or Concomitantly with Other Vaccines: A Population-Based Post-Marketing Surveillance Study"],"prefix":"10.3390","volume":"14","author":[{"given":"Lin","family":"Chang","sequence":"first","affiliation":[{"name":"Liaoning Provincial Center for Disease Control and Prevention, Shenyang 110172, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxi","family":"Liu","sequence":"additional","affiliation":[{"name":"Liaoning Provincial Center for Disease Control and Prevention, Shenyang 110172, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Ren","sequence":"additional","affiliation":[{"name":"Sinovac Holding Group Co., Ltd., Beijing 100085, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Sinovac Biotech Co., Ltd., Beijing 100085, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Fang","sequence":"additional","affiliation":[{"name":"Liaoning Provincial Center for Disease Control and Prevention, Shenyang 110172, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6851-0435","authenticated-orcid":false,"given":"Yurong","family":"Li","sequence":"additional","affiliation":[{"name":"Sinovac Holding Group Co., Ltd., Beijing 100085, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2026, January 27). Poliomyelitis. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/poliomyelitis."},{"key":"ref_2","unstructured":"World Health Organization (2022). Polio Vaccines: WHO Position Paper\u2014June 2022. Wkly. Epidemiol. Rec., 97, 277\u2013300. Available online: https:\/\/www.who.int\/publications\/i\/item\/WHO-WER9725-277-300."},{"key":"ref_3","unstructured":"World Health Organization (2021). Polio Eradication Strategy 2022\u20132026: Delivering on a Promise, WHO."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1093\/infdis\/jiu184","article-title":"Vaccine-associated paralytic poliomyelitis: A review of the epidemiology and estimation of the global burden","volume":"210","author":"Platt","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"101508","DOI":"10.1016\/j.eclinm.2022.101508","article-title":"Global epidemiology of vaccine-derived poliovirus, 2016\u20132021: A descriptive analysis and retrospective case\u2013control study","volume":"50","author":"Lai","year":"2022","journal-title":"eClinicalMedicine"},{"key":"ref_6","unstructured":"World Health Organization, and Strategic Advisory Group of Experts (SAGE) (2022). Evidence-to-Decision: Interchangeability of IPV Vaccines (Including Sabin-Strain IPV), WHO. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/position_paper_documents\/polio\/3-e2d-interchangeability-ipv-vaccines.pdf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/infdis\/jiy736","article-title":"Immunogenicity and safety of a Sabin strain\u2013based inactivated poliovirus vaccine: A phase 3 clinical trial","volume":"220","author":"Hu","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14760584.2021.1919091","article-title":"Cross-neutralization capacity of immune serum from different dosages of Sabin inactivated poliovirus vaccine immunization against multiple polioviruses","volume":"20","author":"Chu","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kai, C., Yurong, L., Sheng, L., Yongmei, S., Jianfeng, W., Xinge, L., Peng, J., and Hongxing, P. (2025). Sustained immune persistence five years post-completion of four-dose sIPV vaccination. Vaccines, 13.","DOI":"10.2139\/ssrn.5071546"},{"key":"ref_10","unstructured":"World Health Organization (2020). Immunization Agenda 2030: A Global Strategy to Leave No One Behind, WHO. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240016514."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1016\/j.vaccine.2017.07.061","article-title":"The benefit of the doubt or doubts over benefits? A systematic literature review of perceived risks of vaccines in European populations","volume":"35","author":"Karafillakis","year":"2017","journal-title":"Vaccine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.vaccine.2014.01.081","article-title":"Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: A systematic review of published literature, 2007\u20132012","volume":"32","author":"Larson","year":"2014","journal-title":"Vaccine"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Hu, J., Han, W., Chu, K., Zhang, H., Tuo, L., Duan, X., Li, J., Yuan, F., Luan, C., and Pan, H. (2025). Immunogenicity and safety of a Sabin strain inactivated poliovirus vaccine booster dose administered separately or concomitantly with inactivated hepatitis A vaccine or measles\u2013mumps\u2013rubella vaccine: A phase 4 randomized controlled trial. Vaccines, 13.","DOI":"10.20944\/preprints202509.2585.v1"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"126183","DOI":"10.1016\/j.vaccine.2024.126183","article-title":"Safety and 6-month immune persistence of Sabin strain inactivated poliovirus vaccine administered simultaneously with other vaccines","volume":"42","author":"Guo","year":"2024","journal-title":"Vaccine"},{"key":"ref_15","first-page":"684","article-title":"Post-marketing safety surveillance of Sabin strain inactivated poliovirus vaccine administered concomitantly with other vaccines in infants and young children in China","volume":"30","author":"Zheng","year":"2024","journal-title":"Chin. J. Vaccines Immun."},{"key":"ref_16","unstructured":"World Health Organization (2016). Global Manual on Surveillance of Adverse Events Following Immunization, WHO. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789241507769."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1080\/14760584.2019.1676154","article-title":"Challenges in evaluating post-licensure vaccine safety: Observations from the Centers for Disease Control and Prevention","volume":"18","author":"Moro","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1016\/j.vaccine.2015.04.060","article-title":"Surveillance of adverse events following immunization in China: Past, present, and future","volume":"33","author":"Liu","year":"2015","journal-title":"Vaccine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijid.2023.10.006","article-title":"Immunogenicity and safety of concomitant administration of the Sabin-strain-based inactivated poliovirus vaccine, the diphtheria\u2013tetanus\u2013acellular pertussis vaccine, and measles\u2013mumps\u2013rubella vaccine to healthy infants aged 18 months in China","volume":"137","author":"Xu","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"127891","DOI":"10.1016\/j.vaccine.2025.127891","article-title":"Immunogenicity and safety of co-administration of Sabin-strain-based inactivated poliovirus vaccine, diphtheria\u2013tetanus\u2013acellular pertussis vaccine, and live attenuated hepatitis A vaccine in 18-month-old children: A multicenter randomized controlled non-inferiority trial in China","volume":"67","author":"Liu","year":"2025","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Wang, B., Meng, F., Xue, W., Su, Y., Jiang, T., Dong, Y., Ren, M., and Tang, J. (2026). Safety of Sabin Inactivated Poliovirus Vaccine Administered Standalone or Concomitantly with Other Childhood Vaccines: A Real-World Study in China. Vaccines, 14.","DOI":"10.3390\/vaccines14020161"},{"key":"ref_22","unstructured":"National Health Commission of the People\u2019s Republic of China, and National Medical Products Administration (2022). Notice on Revising Selected Contents of the National Surveillance Program for Suspected Adverse Events Following Immunization, Document No. 208."},{"key":"ref_23","first-page":"676","article-title":"Surveillance for adverse events following immunization with inactivated poliovirus vaccine in Jiangxi Province, China, 2016\u20132019","volume":"26","author":"Zheng","year":"2020","journal-title":"Chin. J. Vaccines Immun."},{"key":"ref_24","first-page":"28","article-title":"Adverse events following immunization with inactivated poliovirus vaccine and acellular diphtheria\u2013tetanus\u2013pertussis vaccine administered alone or concomitantly in Jilin Province, China","volume":"28","author":"Lin","year":"2022","journal-title":"Chin. J. Vaccines Immun."},{"key":"ref_25","first-page":"1222","article-title":"Surveillance analysis of adverse events following immunization with Sabin strain inactivated poliovirus vaccine in Shaanxi Province, China, 2018\u20132020","volume":"34","author":"Liu","year":"2021","journal-title":"Chin. J. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2387904","DOI":"10.1080\/21645515.2024.2387904","article-title":"Surveillance for Adverse Events Following Immunization in Hebei Province, China, 2018\u20132020","volume":"20","author":"Sun","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_27","first-page":"1299","article-title":"Safety surveillance analysis of three poliovirus vaccines in Hebei Province, China","volume":"27","author":"Sun","year":"2020","journal-title":"Pract. Prev. Med."},{"key":"ref_28","first-page":"1386","article-title":"Post-marketing safety evaluation on inactivated poliovirus vaccine (Vero cells) made from Sabin strain","volume":"32","author":"Liu","year":"2019","journal-title":"Chin. J. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"580","DOI":"10.46234\/ccdcw2025.093","article-title":"Post-marketing surveillance of adverse events following rotavirus vaccination\u2014China, 2013\u20132023","volume":"7","author":"Li","year":"2025","journal-title":"China CDC Wkly."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1898306","DOI":"10.1080\/21645515.2021.1898306","article-title":"Surveillance of adverse events following the introduction of inactivated poliovirus vaccine made from Sabin strains to the Chinese EPI and comparison with wild-strain IPV in Jiangsu, China","volume":"17","author":"Kang","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_31","first-page":"121","article-title":"Surveillance of adverse events following immunization in China, 2023","volume":"31","author":"Zhang","year":"2025","journal-title":"Chin. J. Vaccines Immun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how\u2019s and what\u2019s of vaccine reactogenicity","volume":"4","author":"Didierlaurent","year":"2019","journal-title":"npj Vaccines"},{"key":"ref_33","first-page":"2486","article-title":"Safety Evaluation on Different Doses of Inactivated Poliomyelitis Vaccine","volume":"29","author":"Wang","year":"2020","journal-title":"Chin. J. New Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.2105\/AJPH.85.12.1706","article-title":"The reporting sensitivities of two passive surveillance systems for vaccine adverse events","volume":"85","author":"Rosenthal","year":"1995","journal-title":"Am. J. Public Health"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"10946","DOI":"10.1038\/s41598-022-13809-7","article-title":"Comparability of clinical trials and spontaneous reporting data regarding COVID-19 vaccine safety","volume":"12","author":"Luo","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jadohealth.2013.09.005","article-title":"The role of media and the Internet on vaccine adverse event reporting: A case study of human papillomavirus vaccination","volume":"54","author":"Eberth","year":"2014","journal-title":"J. Adolesc. Health"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/3\/241\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:47:46Z","timestamp":1772790466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/3\/241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["vaccines14030241"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14030241","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]}}}